Behind the Science
Can science change the future of hepatitis B?
In the latest Behind the Science podcast episode, Dr. Kat Arney, Jessica Hicks and Joyeta Das explore one of the world's most overlooked public health challenges: hepatitis B.
Who we are
As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Behind the Science
